PTC Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PTC Therapeutics, Inc.
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.
The US firm’s nanoparticle candidate has disappointed in a late-stage ALS trial but experts say secondary survival data could prove a silver lining given an increasingly flexible US regulatory environment.
Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval.
Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.
- Antisense, Oligonucleotides
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- Agilis Biotherapeutics, Inc.
- Censa Pharmaceuticals Inc.